CWM
SGMO

Cranbrook Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cranbrook Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,620
Closed -$25K – 409
2020
Q4 		$25K Hold
1,620
– – 0.01% 195
2020
Q3 		$15K Hold
1,620
– – ﹤0.01% 195
2020
Q2 		$15K Hold
1,620
– – ﹤0.01% 191
2020
Q1 		$10K Hold
1,620
– – ﹤0.01% 200
2019
Q4 		$14K Hold
1,620
– – ﹤0.01% 195
2019
Q3 		$15K Hold
1,620
– – ﹤0.01% 186
2019
Q2 		$17K Hold
1,620
– – ﹤0.01% 176
2019
Q1 		$15K Hold
1,620
– – ﹤0.01% 185
2018
Q4 		$19K Hold
1,620
– – 0.01% 162
2018
Q3 		$27K Buy
+1,620
New +$24.6K 0.01% 149

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cranbrook Wealth Management's SGMO Position: Q1 2021 in Review

Cranbrook Wealth Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 1,620 shares — an estimated $25K sold.

Cranbrook Wealth Management first reported a position in SGMO in Q3 2018 and held it in 10 quarters. The position peaked at $27K in Q3 2018. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

  • Cranbrook Wealth Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
  • Cranbrook Wealth Management sold 1,620 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $25K.
  • Cranbrook Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 10 quarters.
  • Cranbrook Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $27K in Q3 2018.
  • 203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on Cranbrook Wealth Management's 13F filing for Q1 2021, filed 6 May 2021.